18F-FDG PET/CT in non-small-cell lung cancer patients: a potential predictive biomarker of response to immunotherapy
- Evangelista L.
- Cuppari L.
- Menis J.
- Bonanno L.
- Reccia P.
- Frega S.
- Pasello G.
Publication date
January 2019
DOI Publisher
Ovid Technologies (Wolters Kluwer Health)Abstract
The aim of this study was to assess the predictive role of fluorine-18-fluorodeoxyglucose (F-FDG) PET/computed tomography (CT) in the evaluation of response to immunotherapy in patients affected by metastatic lung cancer
Add to ORKG